Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
暂无分享,去创建一个
David M. Shackleford | G. Drewes | M. Bantscheff | K. Chibale | D. Fidock | F. Gamo | K. Dechering | A. Blagborough | M. Delves | D. Leroy | R. Sauerwein | M. Witty | C. Bodenreider | Marcus C. S. Lee | S. Charman | S. Ghidelli-Disse | K. Marsh | L. Birkholtz | C. Kocken | J. Burrows | M. Lafuente-Monasterio | R. Rochford | M. Jiménez-Díaz | M. Martínez | Iñigo Angulo-Barturen | S. Ferrer | A. Tungtaeng | S. Wittlin | L. Street | S. Solapure | Chek Shik Lim | K. White | Laura M. Sanz | Julia Morizzi | Yassir Younis | A. Zeeman | Rajshekhar Basak | Tara S. Abraham | P. Vanachayangkul | K. Hanson | Diego González Cabrera | A. Ruecker | D. Waterson | Janette Reader | C. Le Manach | S. E. Zakutansky | P. Henrich | C. Donini | C. Scheurer | M. Botha | Tanya Paquet | Janne Mannila | B. Campo | L. Sanz | J. Reader | Anchalee Tungtaeng | Kirsten K. Hanson | Mariette Botha
[1] J. McCarthy,et al. Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development , 2016, Antimicrobial Agents and Chemotherapy.
[2] R. Sauerwein,et al. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites , 2016, Antimicrobial Agents and Chemotherapy.
[3] B. Kuster,et al. Evaluation of Kinase Activity Profiling Using Chemical Proteomics. , 2015, ACS chemical biology.
[4] Farah El Mazouni,et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria , 2015, Science Translational Medicine.
[5] D. Mancama,et al. Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination , 2015, Malaria Journal.
[6] T. Bousema,et al. A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. , 2015, The Journal of antimicrobial chemotherapy.
[7] O. Vandal,et al. Killing the hypnozoite – drug discovery approaches to prevent relapse in Plasmodium vivax , 2015, Pathogens and global health.
[8] David W. Gray,et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis , 2015, Nature.
[9] Scott Emrich,et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria , 2015, Nature.
[10] M. Laufer,et al. Antimalarial drug resistance in Africa: key lessons for the future , 2015, Annals of the New York Academy of Sciences.
[11] P. Gething,et al. Lead Clinical and Preclinical Antimalarial Drugs Can Significantly Reduce Sporozoite Transmission to Vertebrate Populations , 2014, Antimicrobial Agents and Chemotherapy.
[12] Roger Le Grand,et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures , 2014, Nature Medicine.
[13] K. Kuhen,et al. KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage Parasites In Vitro , 2013, Antimicrobial Agents and Chemotherapy.
[14] Robert W. Sauerwein,et al. Targeting Plasmodium PI(4)K to eliminate malaria , 2013, Nature.
[15] K. Chibale,et al. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum , 2013, Malaria Journal.
[16] David M. Shackleford,et al. In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models , 2013, Drug design, development and therapy.
[17] K. Chibale,et al. Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity. , 2013, Journal of medicinal chemistry.
[18] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[19] D. V. van Schalkwyk,et al. Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers , 2013, Malaria Journal.
[20] M. Mota,et al. Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins , 2013, Proceedings of the National Academy of Sciences.
[21] B. Kuster,et al. Measuring and managing ratio compression for accurate iTRAQ/TMT quantification. , 2013, Journal of proteome research.
[22] J. Burrows,et al. Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.
[23] P. Gething,et al. Transmission-blocking interventions eliminate malaria from laboratory populations , 2013, Nature Communications.
[24] Geoffrey L. Johnston,et al. Mitotic Evolution of Plasmodium falciparum Shows a Stable Core Genome but Recombination in Antigen Families , 2013, PLoS genetics.
[25] K. Chibale,et al. Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines. , 2012, Journal of medicinal chemistry.
[26] A. Magill,et al. Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. , 2012, The American journal of tropical medicine and hygiene.
[27] G. Drewes,et al. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. , 2012, Nature chemical biology.
[28] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[29] David M. Shackleford,et al. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. , 2012, Journal of medicinal chemistry.
[30] Jeremy N. Burrows,et al. P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action , 2012, PloS one.
[31] Mark D. Johnson,et al. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion , 2011, Proceedings of the National Academy of Sciences.
[32] Manor Askenazi,et al. Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. , 2011, Analytical chemistry.
[33] S. Hoffman,et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.
[34] D. Kyle,et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) , 2011, Malaria Journal.
[35] M. Mann,et al. Large-scale phosphosite quantification in tissues by a spike-in SILAC method , 2011, Nature Methods.
[36] I. Hastings,et al. Development, Evaluation, and Application of an In Silico Model for Antimalarial Drug Treatment and Failure , 2011, Antimicrobial Agents and Chemotherapy.
[37] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[38] P. Grandi,et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.
[39] Christian Scheurer,et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.
[40] James R. Brown,et al. Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery , 2011, BMC Evolutionary Biology.
[41] Frank Fischer,et al. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays , 2010, Journal of the American Society for Mass Spectrometry.
[42] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[43] David A. Fidock,et al. Drug discovery: Priming the antimalarial pipeline , 2010, Nature.
[44] L. Shultz,et al. Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.
[45] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[46] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[47] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[48] J. Chollet,et al. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. , 2007, Experimental parasitology.
[49] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[50] W. Trager,et al. Human malaria parasites in continuous culture. , 1976, Science.
[51] A. Magill,et al. Primaquine for prophylaxis of malaria: has the CYP sailed? , 2014, Journal of travel medicine.